FDA updates label safety warning for Multaq (Sanofi-Aventis) - 20-Dec-2011

The FDA adds new safety warnings to the label of Multaq (dronedarone), from Sanofi-Aventis, after studies revealed the drug doubles the rate of cardiovascular death, stroke, and heart failure in patients with permanent Atrial Fibrillation. The revised labelling stresses that Multaq is only approved for the short-term form of the condition and a related ailment known as atrial flutter. The update is based on data gathered from the PALLAS and ATHENA trials.

Related News

Related Cardiology Information

Related Cardiology Drugs

Back to top

Latest News

10 May 2015
20 May 2013
20 May 2013